KX 01

Drug Profile

KX 01

Alternative Names: KX-01; KX-2391

Latest Information Update: 26 Dec 2016

Price : $50

At a glance

  • Originator Kinex Pharmaceuticals
  • Developer Athenex; Hanmi Pharmaceutical; Kinex Pharmaceuticals; PharmaEssentia Corporation
  • Class Acetamides; Antineoplastics; Morpholines; Pyridines; Skin disorder therapies; Small molecules
  • Mechanism of Action Angiogenesis inhibitors; Caspase stimulants; Interleukin 2 inhibitors; Keratinocyte inhibitors; Proto-oncogene protein c-bcl-2 inhibitors; Src-Family kinase inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Psoriasis
  • Phase I/II Solid tumours
  • Phase I Actinic keratosis; Acute myeloid leukaemia
  • No development reported Prostate cancer

Most Recent Events

  • 15 Dec 2015 Athenex plans a phase II trial for Actinic keratosis
  • 25 Aug 2015 Phase-II development for Solid tumours is ongoing in South Korea
  • 01 Dec 2014 Phase-I clinical trials in Actinic keratosis in USA (Topical) (NCT02337205)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top